ÂÜÀòÂÒÂ×

Ms. Harrington-Smith joined ImmunoGen in November 2021 with over 20 years of experience in the pharmaceutical industry. Most recently, she served as US Commercial Head of Hematology at Novartis Pharmaceuticals, where she led the commercial teams responsible for a portfolio of therapies in both benign and malignant hematologic diseases including acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome, idiopathic thrombocytopenic purpura, sickle cell disease, and paroxysmal nocturnal hemoglobinuria. In previous roles of increasing seniority at Novartis, Ms. Harrington-Smith was responsible for the commercial launch of Kymriah®, the first CAR-T cell therapy, building management, sales, marketing, and market access teams, and supporting the launch of Gilenya® for the treatment of multiple sclerosis. Ms. Harrington-Smith received a BA from Williams College and an MBA from the Kenan-Flagler Business School at the University of North Carolina.